Clinical Trial Update: Effect of Fingolimod on Neurodegeneration [Phase 4]

View source ↗

Summary

Phase 4 trial update on fingolimod assessing effects on cognition and brain volume, terminated with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Atrophy
• Cognitive Disorders
• Neurodegeneration

Drugs mentioned

• Fingolimod (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cognition, Brain Volume Loss | Phase 4 | Status: TERMINATED | Results posted: 2019-02-27